CACI International Inc (NYSE: CACI) has been awarded a five-year task order worth over $306 million to enhance the Defense Agencies Initiative's Global Model for the Defense Logistics Agency. This contract highlights CACI's role in modernizing financial processes within the Department of Defense and supporting national security. Despite strong growth potential and profitability indicated by its GF Score™ of 95/100, insider selling activity totaling $1.4 million in the last three months suggests a need for investor caution.

The Progressive Corporation reported a 6% increase in Q1 net premiums written, reaching $23.64 billion, and a 10% rise in net income to $2.82 billion. Earnings per share also grew by 10% to $4.80. The company's profitability and undervalued stock status, as suggested by InvestingPro, are highlighted alongside policy growth across various lines of business.

Truist has lowered its price target for Insulet (NASDAQ: PODD) to $315 from $360, while maintaining a Buy rating on the stock. This adjustment follows similar actions by other firms like RBC, BTIG Research, and Goldman Sachs, who have also reduced their price targets for Insulet recently, though mostly retaining favorable ratings. Insulet specializes in medical devices for insulin-dependent diabetes and non-insulin drug delivery systems.

CACI International Inc (NYSE:CACI) has been awarded a five-year task order valued at up to $306 million by the Defense Logistics Agency. Under the contract, CACI will provide Agile software development, enhancement, and maintenance for the Global Model used by the Defense Agencies Initiative, aiming to improve financial management and data transparency. The contract represents approximately 3.4% of CACI's annual revenue and follows other recent strategic moves like the acquisition of ARKA Group L.P. and an $85 million contract with the U.S. Navy.

Baird has adjusted its price target for Intuitive Surgical (ISRG) to $575, down from $645, while retaining an "Outperform" rating on the stock. This adjustment reflects an updated valuation for the medical equipment company.

Wells Fargo has increased its price target for Nucor (NUE) to $213 from $197, while reaffirming an Overweight rating on the stock. This adjustment reflects a positive outlook from the analyst firm on the steel production group. The article also notes similar price target adjustments from other firms like JPMorgan and Jefferies, indicating broader analyst interest in Nucor.

Kimberly-Clark Corporation announced its post-closing organizational structure and key leadership team in anticipation of completing its acquisition of Kenvue Inc. The new structure will feature four business segments: North America, Asia Pacific Focus Markets, EMEA, and Enterprise Markets. Mike Hsu will continue as Chairman and CEO, leading a team designed for agility and speed to capitalize on growth opportunities in the health and wellness sector.

Levi & Korsinsky, LLP is investigating Insulet Corp. (NASDAQ: PODD) for potential securities fraud after the company disclosed a voluntary medical device correction for its Omnipod 5 insulin pods due to a design defect causing insulin leakage, which has been linked to eighteen serious adverse events. This disclosure caused Insulet shares to drop by approximately 6.9%. The investigation will focus on whether Insulet executives concealed knowledge of this defect prior to the public announcement on March 12, 2026.

CBIZ (NYSE: CBZ) will report its first-quarter 2026 financial results after markets close on April 29, 2026. A conference call with CEO Jerry Grisko and CFO Brad Lakhia is scheduled for 5:00 p.m. ET on the same day, which will be webcast live and archived on the company's investor relations website. Investors are encouraged to register and dial in early to avoid delays.

Blackbaud (NASDAQ: BLKB) is scheduled to report its first-quarter FY2026 financial results on Wednesday, April 29, 2026, at 8:00 a.m. ET, before U.S. markets open. The company will also host a conference call and live webcast at the same time to discuss the results, with an archive available on its investor webpage. Historically, similar earnings date announcements have been followed by a modest negative market reaction.